Pioneers and Heroes

In early 2011, after the publication of Dr. Arguello’s book, “Atavistic Metamorphosis: A New and Logical Explanation of the Origin and Biological Nature of Cancer,” the Atavistic Chemotherapy Clinical Trial commenced. For the first eight years, many trial participants were patients discharged from reputable hospitals, primarily in Canada, Mexico, and the United States, following extended periods of ineffective conventional treatments, including chemotherapy and radiation.

Dr. Arguello discovered that patients who had previously had extensive treatment with standard chemotherapy showed temporary responses to atavistic chemotherapy, as opposed to individuals who had never received such treatment before. In other words, while some patients may enjoy partial or total clinical remission with atavistic chemotherapy, most of them will eventually experience a recurrence about a year later. A few other previously treated patients did not respond to the treatment. According to recent medical reports, typical anticancer medications affect the biology of cancer cells over time, resulting in higher proliferation, more aggressive behavior, distant metastases, and resistance to other anticancer therapies, such as atavistic chemotherapy in our experience. These incidents occur after months of an apparent anticancer response (see section “Don’t Waste Your Life” above).

In 2019, Dr. Arguello ended his one-month no-payment treatment trial for patients who had previously been subjected to conventional chemotherapy or radiation for an extended period of time, citing a low chance of a cure. Dr. Arguello remains dedicated to finding ways to overcome the resistance caused by conventional anticancer treatments, and he continues enrolling patients who have previously undergone traditional anticancer therapies, provided they express interest; he believes that a one-month trial is worthwhile to assess their response.

The portrait photographs in “Pioneers and Heroes” depict some of the patients who received extensive treatment with traditional chemotherapy or radiation before participating in our trial. We commend their courage in challenging the status quo and pursuing a more rational approach to cancer, which enabled Dr. Arguello to develop and refine what is now recognized as atavistic chemotherapy.